Alfuzosin is an alpha-adrenergic blocker indicated for the treatment of signs and symptoms of benign prostatic hyperplasia, among other approved uses. It is available as extended-release tablets and tablets for oral use. MedsAcross supplies Alfuzosin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
UROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. Important Limitations of Use: UROXATRAL is not indicated for treatment of hypertension. UROXATRAL is not indicated for use in the pediatric population.
Source: US FDA prescribing information
Alfuzosin is a selective antagonist of post-synaptic alpha 1 -adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.
Source: US FDA prescribing information
The recommended dosage is one 10 mg UROXATRAL (alfuzosin HCl) extended-release tablet once daily. The extent of absorption of alfuzosin is 50% lower under fasting conditions. Therefore, Uroxatral should be taken with food and with the same meal each day. The tablets should not be chewed or crushed. 10 mg once daily with food and with the same meal each day. Tablets should not be chewed or crushed
Source: US FDA prescribing information
UROXATRAL is contraindicated for use: in patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients. with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased. in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of UROXATRAL tablets Moderate or severe hepatic impairment. Co-administration with potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir). Known hypersensitivity (e.g., urticaria or angioedema) to alfuzosin or any of the ingredients
Source: US FDA prescribing information
Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates. Use with caution in patients with severe renal impairment (creatinine clearance <30 mL/min). Use with caution in patients with mild hepatic impairment. Should not be used in combination with other alpha adrenergic antagonists. Prostate carcinoma should be ruled out prior to treatment. Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery may require modifications to the surgical technique. Discontinue UROXATRAL if symptoms of angina pectoris appear or worsen. Use with caution in patients with a history of QT prolongation or who are taking medications which prolong the QT interval
Source: US FDA prescribing information
Most common adverse reactions in clinical studies (incidence ≥2% and at a higher incidence than placebo): dizziness, upper respiratory tract infection, headache, fatigue.
Source: US FDA prescribing information
Concomitant use of PDE5 inhibitors with alpha adrenergic antagonists, including UROXATRAL, can potentially cause symptomatic hypotension
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F). Protect from light and moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Alfuzosin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Alfuzosin 10 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Alfuzosin 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Uroxatral 10 mg extended-release tabletOral | Advanz Pharma | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 12 June 2003 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Alfuzosin in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Alfuzosin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Alfuzosin, including Uroxatral.
Yes. The US FDA first approved Alfuzosin on 12 June 2003, according to Drugs@FDA.
No listed presentation of Alfuzosin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Alfuzosin is classified under ATC code G04CA01 (Alfuzosin).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.